Cipla Ltd.
BSE: 500087 | NSE: CIPLA
Large Cap | Pharmaceuticals & Drugs
1356.50
3.50 (0.26%) USFDA completes cGMP inspection at Cipla’s arm’s New York facility
Date: 23-10-2026The United States Food and Drug Administration (USFDA) has conducted an inspection at the manufacturing facility of InvaGen Pharmaceuticals Inc. (InvaGen), wholly owned subsidiary of Cipla, located in Hauppauge, Long Island, New York, USA. The inspection was conducted from October 19, 2026 to October 22, 2026 (ET). The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. The inspection concluded with zero Form 483 observations.
Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).